Photodynamic therapy in the management of pre-malignant head and neck mucosal dysplasia and microinvasive carcinoma

Photodiagnosis and Photodynamic Therapy

Volumn 8, Issue 2, 2011, Pages 75-85

  Quon, Harry ^a,b,c,d   Grossman, Craig E ^a,d   Finlay, Jarod C ^a,d   Zhu, Timothy C ^a,d   Clemmens, Clarice S ^b,d   Malloy, Kelly M ^b,c,d   Busch, Theresa M ^a,d  

^a Department of Radiation Oncology ^*  (United States)

^b Department of Otorhinolaryngology   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Head and neck premalignant dysplasia; Microinvasive carcinoma; PDT; Photodynamic therapy; Review

Indexed keywords

AMINOLEVULINIC ACID; LUTETIUM TEXAPHYRIN; PHOTOFRIN; PROTOPORPHYRIN; TEMOPORFIN; VERTEPORFIN;

CANCER RISK; CARCINOMA IN SITU; CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DYSPLASIA; EXTERNAL BEAM RADIOTHERAPY; FIBROSIS; FOLLOW UP; HEAD AND NECK CARCINOMA; HEAD AND NECK DYSPLASIA; HUMAN; INVASIVE CARCINOMA; LARYNX CARCINOMA; MALIGNANT TRANSFORMATION; MOUTH CARCINOMA; PHOTODYNAMIC THERAPY; PRECANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ROBOTICS; TREATMENT OUTCOME; TREATMENT RESPONSE;

HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASMS, SQUAMOUS CELL; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PRECANCEROUS CONDITIONS;

EID: 79954569181     PISSN: 15721000     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pdpdt.2011.01.001     Document Type: Review

References (67)

1. Pignon J.-P., le Maître A., Bourhis J. Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys 2007, 69(2 Suppl. 1):S112-S114.
2. Bourhis J., Overgaard J., Audry H., Ang K.K., Saunders M., Bernier J., et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006, 368(9538):843-854.
3. Langendijk J.A., Doornaert P., Rietveld D.H., Verdonck-de Leeuw I.M., Leemans C.R., Slotman B.J. A predictive model for swallowing dysfunction after curative radiotherapy in head and neck cancer. Radiother Oncol 2009, 90(2):189-195.
4. Machtay M., Moughan J., Trotti A., Garden A.S., Weber R.S., Cooper J.S., et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 2008, 26(21):3582-3589.
5. Smith J., Rattay T., McConkey C., Helliwell T., Mehanna H. Biomarkers in dysplasia of the oral cavity: a systematic review. Oral Oncol 2009, 45(8):647-653.
6. Mehanna H.M., Rattay T., Smith J., McConkey C.C. Treatment and follow-up of oral dysplasia - a systematic review and meta-analysis. Head Neck 2009, 31(12):1600-1609.
7. Stefano P. Pooled estimate of world leukoplakia prevalence: a systematic review. Oral Oncol 2003, 39(8):770-780.
8. Weller M.D., Nankivell P.C., McConkey C., Paleri V., Mehanna H.M. The risk and interval to malignancy of patients with laryngeal dysplasia; a systematic review of case series and meta-analysis. Clin Otolaryngol 2010, 35(5):364-372.
9. Al-Dakkak I. Oral dysplasia and risk of progression to cancer. Evid Based Dent 2010, 11(3):91-92.
10. Yang S.W., Wu C.J., Lee Y.S., Chen T.A., Tsai C.N. Postoperative recurrence as an associated factor of malignant transformation of oral dysplastic leukoplakia. ORL J Otorhinolaryngol Relat Spec 2010, 72(5):280-290.
11. Rosin M.P., Cheng X., Poh C., Lam W.L., Huang Y., Lovas J., et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res 2000, 6(2):357-362.
12. van der Waal I., Schepman K.P., van der Meij E.H., Smeele L.E. Oral leukoplakia: a clinicopathological review. Oral Oncol 1997, 33(5):291-301.
13. Damm M., Sittel C., Streppel M., Eckel H.E. Transoral CO2 laser for surgical management of glottic carcinoma in situ. Laryngoscope 2000, 110(7):1215-1221.
14. Sadri M., McMahon J., Parker A. Management of laryngeal dysplasia: a review. Eur Arch Otorhinolaryngol 2006, 263(9):843-852.
15. Pitiyage G., Tilakaratne W.M., Tavassoli M., Warnakulasuriya S. Molecular markers in oral epithelial dysplasia: review. J Oral Pathol Med 2009, 38(10):737-752.
16. Lodi G., Sardella A., Bez C., Demarosi F., Carrassi A. Interventions for treating oral leukoplakia. Cochrane Database Syst Rev 2006, 4:CD001829.
17. Epstein J.B., Gorsky M., Fischer D., Gupta A., Epstein M., Elad S. A survey of the current approaches to diagnosis and management of oral premalignant lesions. J Am Dent Assoc (1939) 2007, 138(12):1555-1562. quiz 614.
18. Hamadah O., Thomson P.J. Factors affecting carbon dioxide laser treatment for oral precancer: a patient cohort study. Lasers Surg Med 2009, 41(1):17-25.
19. Grossman C., Zhu T., Finlay J., Dimofte A., Malloy K., O'Malley B., et al. Targeted laryngeal photodynamic therapy with a balloon diffusing light source. Photodiagnosis Photodyn Ther 2010, 7(3):158-161.
20. Wang H.W., Putt M.E., Emanuele M.J., Shin D.B., Glatstein E., Yodh A.G., et al. Treatment-induced changes in tumor oxygenation predict photodynamic therapy outcome. Cancer Res 2004, 64(20):7553-7561.
21. Ishimaru A. Wave propagation and scattering in random media 1997, IEEE Press, New York.
22. Henderson B.W., Gollnick S.O., Snyder J.W., Busch T.M., Kousis P.C., Cheney R.T., et al. Choice of oxygen-conserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors. Cancer Res 2004, 64(6):2120-2126.
23. Busch T.M., Xing X., Yu G., Yodh A., Wileyto E.P., Wang H.W., et al. Fluence rate-dependent intratumor heterogeneity in physiologic and cytotoxic responses to Photofrin photodynamic therapy. Photochem Photobiol Sci 2009, 8(12):1683-1693.
24. Middelburg TA, van Zaane F, de Bruijn HS, van der Ploeg-van den Heuvel A, Sterenborg HJ, Neumann HA, et al. Fractionated Illumination at low fluence rate photodynamic therapy in mice. Photochem Photobiol.
25. Angell-Petersen E., Spetalen S., Madsen S.J., Sun C.H., Peng Q., Carper S.W., et al. Influence of light fluence rate on the effects of photodynamic therapy in an orthotopic rat glioma model. J Neurosurg 2006, 104(1):109-117.
26. Cottrell W.J., Paquette A.D., Keymel K.R., Foster T.H., Oseroff A.R. Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. Clin Cancer Res 2008, 14(14):4475-4483.
27. Robinson D.J., de Bruijn H.S., Star W.M., Sterenborg H.J. Dose and timing of the first light fraction in two-fold illumination schemes for topical ALA-mediated photodynamic therapy of hairless mouse skin. Photochem Photobiol 2003, 77(3):319-323.
28. Star W.M., van't Veen A.J., Robinson D.J., Munte K., de Haas E.R., Sterenborg H.J. Topical 5-aminolevulinic acid mediated photodynamic therapy of superficial basal cell carcinoma using two light fractions with a two-hour interval: long-term follow-up. Acta Derm Venereol 2006, 86(5):412-417.
29. Curnow A., McIlroy B.W., Postle-Hacon M.J., MacRobert A.J., Bown S.G. Light dose fractionation to enhance photodynamic therapy using 5-aminolevulinic acid in the normal rat colon. Photochem Photobiol 1999, 69(1):71-76.
30. Messmann H., Mlkvy P., Buonaccorsi G., Davies C.L., MacRobert A.J., Bown S.G. Enhancement of photodynamic therapy with 5-aminolaevulinic acid-induced porphyrin photosensitisation in normal rat colon by threshold and light fractionation studies. Br J Cancer 1995, 72(3):589-594.
31. Curnow A., Haller J.C., Bown S.G. Oxygen monitoring during 5-aminolaevulinic acid induced photodynamic therapy in normal rat colon. Comparison of continuous and fractionated light regimes. J Photochem Photobiol B Biol 2000, 58(2-3):149-155.
32. Curnow A., Bown S.G. The role of reperfusion injury in photodynamic therapy with 5-aminolaevulinic acid - a study on normal rat colon. Br J Cancer 2002, 86(6):989-992.
33. Pogue B.W., O'Hara J.A., Goodwin I.A., Wilmot C.J., Fournier G.P., Akay A.R., et al. Tumor PO(2) changes during photodynamic therapy depend upon photosensitizer type and time after injection. Comp Biochem Physiol A Mol Integr Physiol 2002, 132(1):177-184.
34. Korbelik M., Krosl G. Cellular levels of photosensitisers in tumours: the role of proximity to the blood supply. Br J Cancer 1994, 70(4):604-610.
35. Chen B., Crane C., He C., Gondek D., Agharkar P., Savellano M.D., et al. Disparity between prostate tumor interior versus peripheral vasculature in response to verteporfin-mediated vascular-targeting therapy. Int J Cancer 2008, 123(3):695-701.
36. Busch T.M., Wang H.W., Wileyto E.P., Yu G., Bunte R.M. Increasing damage to tumor blood vessels during motexafin lutetium-PDT through use of low fluence rate. Radiat Res 2010, 174(3):331-340.
37. Li L.B., Luo R.C. Effect of drug-light interval on the mode of action of Photofrin photodynamic therapy in a mouse tumor model. Lasers Med Sci 2009, 24(4):597-603.
38. Chen B., Pogue B.W., Hoopes P.J., Hasan T. Combining vascular and cellular targeting regimens enhances the efficacy of photodynamic therapy. Int J Radiat Oncol Biol Phys 2005, 61(4):1216-1226.
39. Star W. The relationship between integrating sphere and diffusion theory calculations of fluence rate at the wall of a spherical cavity. Phys Med Biol 1995, 40:1-8.
40. Tan I.B., Oppelaar H., Ruevekamp M.C., Veenhuizen R.B., Timmers A., Stewart F.A. The importance of in situ light dosimetry for photodynamic therapy of oral cavity tumors. Head Neck 1999, 21(5):434-441.
41. Mourant J.R., Freyer J.P., Hielscher A.H., Eick A.A., Shen D., Johnson T.M. Mechanisms of light scattering from biological cells relevant to noninvasive optical-tissue diagnosis. Appl Opt 1998, 37:3586-3593.
42. Vulcan T.G., Zhu T.C., Rodriguez C.E., Hsi A., Fraker D.L., Baas P., et al. Comparison between isotropic and nonisotropic dosimetry systems during intraperitoneal photodynamic therapy. Lasers Surg Med 2000, 26(3):292-301.
43. Zaidi S.I., Oleinick N.L., Zaim M.T., Mukhtar H. Apoptosis during photodynamic therapy-induced ablation of RIF-1 tumors in C3H mice: electron microscopic, histopathologic and biochemical evidence. Photochem Photobiol 1993, 58(6):771-776.
44. Oleinick N.L., Morris R.L., Belichenko I. The role of apoptosis in response to photodynamic therapy: what, where, why, and how. Photochem Photobiol Sci 2002, 1(1):1-21.
45. Kessel D., Vicente M.G., Reiners J.J. Initiation of apoptosis and autophagy by photodynamic therapy. Autophagy 2006, 2(4):289-290.
46. Korbelik M., Dougherty G.J. Photodynamic therapy-mediated immune response against subcutaneous mouse tumors. Cancer Res 1999, 59(8):1941-1946.
47. Gollnick SO, Brackett CM. Enhancement of anti-tumor immunity by photodynamic therapy. Immunol Res 46(1-3):216-26.
48. Moor A.C. Signaling pathways in cell death and survival after photodynamic therapy. J Photochem Photobiol 2000, 57(1):1-13.
49. Hahn S.M., Putt M.E., Metz J., Shin D.B., Rickter E., Menon C., et al. Photofrin uptake in the tumor and normal tissues of patients receiving intraperitoneal photodynamic therapy. Clin Cancer Res 2006, 12(18):5464-5470.
50. Stepp H., Beck T., Pongratz T., Meinel T., Kreth F.W., Tonn J., et al. ALA and malignant glioma: fluorescence-guided resection and photodynamic treatment. J Environ Pathol Toxicol Oncol 2007, 26(2):157-164.
51. Wang C.Y., Tsai T., Chiang C.P., Chen H.M., Chen C.T. Improved diagnosis of oral premalignant lesions in submucous fibrosis patients with 5-aminolevulinic acid induced PpIX fluorescence. J Biomed Opt 2009, 14(4):044026.
52. Taroni P., Pifferi A., Torricelli A., Comelli D., Cubeddu R. In vivo absorption and scattering spectroscopy of biological tissues. Photochem Photobiol Sci 2003, 2(2):124-129.
53. Biel M.A. Photodynamic therapy treatment of early oral and laryngeal cancers. Photochem Photobiol 2007, 83(5):1063-1068.
54. Nyst H.J., van Veen R.L., Tan I.B., Peters R., Spaniol S., Robinson D.J., et al. Performance of a dedicated light delivery and dosimetry device for photodynamic therapy of nasopharyngeal carcinoma: phantom and volunteer experiments. Lasers Surg Med 2007, 39(8):647-653.
55. Weinstein G.S., O'Malley B.W., Snyder W., Sherman E., Quon H. Transoral robotic surgery: radical tonsillectomy. Arch Otolaryngol Head Neck Surg 2007, 133(12):1220-1226.
56. O'Malley B.W., Weinstein G.S., Snyder W., Hockstein N.G. Transoral robotic surgery (TORS) for base of tongue neoplasms. Laryngoscope 2006, 116(8):1465-1472.
57. Grant W.E., Hopper C., Speight P.M., Macrobert A.J., Bown S.G. Photodynamic therapy of malignant and premalignant lesions in patients with 'field cancerization' of the oral cavity. J Laryngol Otol 1993, 107(12):1140-1145.
58. Rigual N.R., Thankappan K., Cooper M., Sullivan M.A., Dougherty T., Popat S.R., et al. Photodynamic therapy for head and neck dysplasia and cancer. Arch Otolaryngol Head Neck Surg 2009, 135(8):784-788.
59. Copper M.P., Triesscheijn M., Tan I.B., Ruevekamp M.C., Stewart F.A. Photodynamic therapy in the treatment of multiple primary tumours in the head and neck, located to the oral cavity and oropharynx. Clin Otolaryngol 2007, 32(3):185-189.
60. Savary J.F., Monnier P., Fontolliet C., Mizeret J., Wagnieres G., Braichotte D., et al. Photodynamic therapy for early squamous cell carcinomas of the esophagus, bronchi, and mouth with m-tetra (hydroxyphenyl) chlorin. Arch Otolaryngol Head Neck Surg 1997, 123(2):162-168.
61. Fan K.F., Hopper C., Speight P.M., Buonaccorsi G.A., Bown S.G. Photodynamic therapy using mTHPC for malignant disease in the oral cavity. Int J Cancer 1997, 73(1):25-32.
62. Chen H.M., Yu C.H., Tu P.C., Yeh C.Y., Tsai T., Chiang C.P. Successful treatment of oral verrucous hyperplasia and oral leukoplakia with topical 5-aminolevulinic acid-mediated photodynamic therapy. Lasers Surg Med 2005, 37(2):114-122.
63. Sieron A., Adamek M., Kawczyk-Krupka A., Mazur S., Ilewicz L. Photodynamic therapy (PDT) using topically applied delta-aminolevulinic acid (ALA) for the treatment of oral leukoplakia. J Oral Pathol Med 2003, 32(6):330-336.
64. Yu C.H., Lin H.P., Chen H.M., Yang H., Wang Y.P., Chiang C.P. Comparison of clinical outcomes of oral erythroleukoplakia treated with photodynamic therapy using either light-emitting diode or laser light. Lasers Surg Med 2009, 41(9):628-633.
65. Kubler A., Haase T., Rheinwald M., Barth T., Muhling J. Treatment of oral leukoplakia by topical application of 5-aminolevulinic acid. Int J Oral Maxillofac Surg 1998, 27(6):466-469.
66. Fan K.F., Hopper C., Speight P.M., Buonaccorsi G., MacRobert A.J., Bown S.G. Photodynamic therapy using 5-aminolevulinic acid for premalignant and malignant lesions of the oral cavity. Cancer 1996, 78(7):1374-1383.
67. Ma G., Ikeda H., Inokuchi T., Sano K. Effect of photodynamic therapy using 5-aminolevulinic acid on 4-nitroquinoline-1-oxide-induced premalignant and malignant lesions of mouse tongue. Oral Oncol 1999, 35(1):120-124.